24-week, randomized, double blind, placebo-controlled trial to evaluate safety and efficacy
of canagliflozin as compared with placebo in reducing the need for mealtime insulin in
subjects with type 2 diabetes currently using a basal-bolus insulin regimen.
Phase:
Phase 4
Details
Lead Sponsor:
Atlanta Research and Education Foundation Foundation for Atlanta Veterans Education and Research, Inc.